Developer docs
API playgroundTry for free, no card

Search company profiles

Phare Bio

Full company profile

uuid0006hi3

Namestring
Phare Bio
Legal namestring
Phare Bio Inc.
Websiteurl
pharebio.org
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Phare Bio is a nonprofit social venture founded in 2020 that applies generative AI and deep learning to discover novel classes of antibiotics, with the stated mission of addressing the global antimicrobial resistance (AMR) crisis. Its core product is AIBiotics, a generative AI discovery platform developed in partnership with the Collins Lab at MIT that screens 1000x more molecules at 5x speed and 100x greater success rate than traditional approaches, combining fragment-based screening with de novo compound generation. The platform has produced peer-reviewed results in Cell and Nature (2025), including two lead candidates (NG1 and DN1) demonstrating bactericidal efficacy against drug-resistant pathogens in mouse models, and is supported by an ARPA-H grant to design 15 new antibiotics as preclinical candidates.

The business model is a hybrid social venture that bifurcates funding sources by development stage. Donor and grant capital (TED's Audacious Project at founding, a $27 million ARPA-H award in September 2024, and Google.org's Generative AI Accelerator in 2025) funds preclinical discovery through the "valley of death" where most antibiotic programs fail. Once candidates are de-risked preclinically, Phare Bio advances them through strategic commercial partnerships — most notably with Basilea Pharmaceutica (announced December 2025), which includes success-based payments — or through company spin-outs intended to provide a sustainable clinical path to patients. The company does not sell products directly and pricing is not publicly disclosed; revenue mechanics are tied to grant inflows and contingent milestone payments rather than commercial sales.

Phare Bio serves global healthcare systems facing the AMR crisis and large pharmaceutical companies seeking to replenish depleted antibiotic pipelines, targeting urgent threats such as Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Its GTM motion is enterprise partnership-led, leveraging the scientific credibility of the Collins Lab and a senior advisory bench drawn from GSK, Merck, Pfizer, Johnson & Johnson, and Evotec to secure co-development deals. The organization operates as a going concern with a small core team (1-10 employees per firmographics) supplemented by an extensive advisor network.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
AI drug discovery, antibiotic discovery platform, antimicrobial resistance therapeutics, generative AI drug design, preclinical drug development
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAJAF
Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
AI-enabled antibiotic drug discovery
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Philanthropic/Grant Funding
TypeLicensing Royalties
Description

Phare Bio operates as a nonprofit social venture funded primarily through grants and donations. The company addresses the 'valley of death' in preclinical development with donor funding from organizations including TED's Audacious Project, ARPA-H ($27 million), and Google.org

pharebio.org
2Strategic Commercial Partnerships
TypeLicensing Royalties
Description

Once candidates are derisked through preclinical development, Phare partners with large pharma companies for clinical trials, or spins out new companies. The Basilea partnership includes success-based payments for advancing novel antibiotics

globenewswire.com
3Company Spin-outs
TypeLicensing Royalties
Description

Phare Bio develops a novel pipeline of AI-optimized antibiotic candidates and builds sustainable clinical paths through company spin-outs for long-term sustainability

engine.xyz
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1AIBiotics
Description

The world's first generative AI antibiotics discovery engine designed to design and develop novel antibiotics against urgent threats like Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae.

pharebio.org
Core offering1 text field

Phare Bio is a nonprofit social venture that uses generative AI and deep learning (the AIBiotics platform, built with the Collins Lab at MIT) to design and develop novel classes of antibiotics against drug-resistant pathogens. The company performs preclinical discovery and development using donor funding and then advances candidates into clinical trials through strategic pharmaceutical partnerships (e.g., Basilea) or company spin-outs. Its immediate customers are pharmaceutical partners and grant/foundation funders, not end patients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Screens 1000x as many molecules, 5x faster, at 100x greater success rate
+2 more records
Product overview1 text field

Phare Bio is a social venture offering a unified AI-driven antibiotic discovery platform called AIBiotics. The platform integrates generative AI and deep learning capabilities to design novel antibiotics, followed by hit-to-lead optimization (drug metabolism, toxicology, pharmacokinetics, and efficacy assays) and preclinical development (drug delivery and in vivo efficacy profiling). The company addresses the antibiotic development pipeline from initial discovery through preclinical stages, then partners with large pharma companies or spins out new companies for clinical trials.

Product and service1 record
1AIBiotics Generative AI Discovery Platform
CategoryAI-enabled drug discovery platform
Description

AIBiotics is Phare Bio's proprietary generative AI and deep learning platform for designing and developing novel antibiotics against drug-resistant pathogens such as Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. It screens 1000x as many molecules, 5x faster, and at 100x greater success rate than conventional approaches, integrating fragment-based screening with de novo compound generation and feeding downstream hit-to-lead optimization and preclinical development. It is used internally by Phare Bio's science team and, via strategic partnerships and spin-outs, is the technology backbone for advancing candidates into clinical development with pharmaceutical partners.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-14
Description

Phare Bio and Basilea Pharmaceuticals partnered to develop antimicrobials, leveraging AI to advance molecules from discovery through clinical trials. The collaboration involves CEO Akhila Kosaraju, MD discussing innovation in antibiotic development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-11
Description

Basilea Pharmaceutica and Phare Bio entered a partnership to develop a novel antibiotic using AI-driven molecule design. The collaboration aims to address antimicrobial resistance by combining Basilea's anti-infectives industry expertise with Phare's unique AI capabilities. Phare Bio is eligible for success-based payments.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Basilea announced preclinical partnership with Prokaryotics Inc. for broad-spectrum antifungal development, alongside the Phare Bio partnership for AI-assisted antibiotic discovery.

4MIT Collins Lab
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Core partnership with James J. Collins' laboratory at MIT for building the first-ever generative AI platform for novel antibiotic discovery. The lab pioneered AI-driven antibiotic discovery including the halicin breakthrough in 2020 and more recently generative AI-designed antibiotics published in Cell 2025.

miragenews.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-enabled drug discovery platform combining high-throughput biology with machine learning to identify novel therapeutics; a direct competitor to Phare in the AI-for-drug-discovery space with publicly disclosed pipeline assets.

TypeDirect peer
Description

Machine learning-driven drug discovery company using AI/ML platforms to design novel therapeutics — directly comparable to Phare's generative AI approach for antibiotic discovery, though broader in therapeutic scope.

3Iambic Therapeutics
TypeDirect peer
Description

AI-driven drug discovery company using physics-informed machine learning to design novel small-molecule therapeutics; directly comparable in deploying generative AI for small-molecule design with platform-licensing economics.

TypeDirect peer
Description

Computational chemistry and physics-based drug design platform widely used by pharma; highly comparable as a software-driven small-molecule discovery peer, with both internal pipeline and platform-licensing economics.

TypeDirect peer
Description

AI-powered generative biology platform combining wet-lab and computational methods to design novel antibody therapeutics; comparable platform-based AI drug discovery approach with public-company scale.

TypeDirect peer
Description

Harvard spin-out developing a novel class of antibacterials; directly comparable as an early-stage anti-infectives discovery company targeting drug-resistant pathogens, with overlapping scientific founders in the AMR space.

TypeDirect peer
Description

AI-driven small molecule drug discovery company using deep learning to design novel therapeutics; comparable platform approach to Phare with broader therapeutic-area focus.

TypeDirect peer
Description

AI-enabled antibacterial discovery biotech developing novel antibiotics against drug-resistant pathogens; closely comparable focus area to Phare Bio's anti-infectives mission.

TypeDirect peer
Description

Generative AI platform for designing novel protein-based therapeutics; comparable in deploying generative biology at scale to create drug candidates de novo, though focused on biologics rather than small molecules.

10Isomorphic Labs
TypeBroad incumbent
Description

Alphabet/DeepMind's drug discovery spin-out using AlphaFold-derived AI for computational drug design; a well-capitalized incumbent applying similar AI methodology to therapeutic discovery at much larger scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Phare Bio

AI-enabled antibiotic drug discoverypharebio.org

What Phare Bio does

Phare Bio is a nonprofit social venture founded in 2020 that applies generative AI and deep learning to discover novel classes of antibiotics, with the stated mission of addressing the global antimicrobial resistance (AMR) crisis. Its core product is AIBiotics, a generative AI discovery platform developed in partnership with the Collins Lab at MIT that screens 1000x more molecules at 5x speed and 100x greater success rate than traditional approaches, combining fragment-based screening with de novo compound generation. The platform has produced peer-reviewed results in Cell and Nature (2025), including two lead candidates (NG1 and DN1) demonstrating bactericidal efficacy against drug-resistant pathogens in mouse models, and is supported by an ARPA-H grant to design 15 new antibiotics as preclinical candidates.

The business model is a hybrid social venture that bifurcates funding sources by development stage. Donor and grant capital (TED's Audacious Project at founding, a $27 million ARPA-H award in September 2024, and Google.org's Generative AI Accelerator in 2025) funds preclinical discovery through the "valley of death" where most antibiotic programs fail. Once candidates are de-risked preclinically, Phare Bio advances them through strategic commercial partnerships — most notably with Basilea Pharmaceutica (announced December 2025), which includes success-based payments — or through company spin-outs intended to provide a sustainable clinical path to patients. The company does not sell products directly and pricing is not publicly disclosed; revenue mechanics are tied to grant inflows and contingent milestone payments rather than commercial sales.

Phare Bio serves global healthcare systems facing the AMR crisis and large pharmaceutical companies seeking to replenish depleted antibiotic pipelines, targeting urgent threats such as Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Its GTM motion is enterprise partnership-led, leveraging the scientific credibility of the Collins Lab and a senior advisory bench drawn from GSK, Merck, Pfizer, Johnson & Johnson, and Evotec to secure co-development deals. The organization operates as a going concern with a small core team (1-10 employees per firmographics) supplemented by an extensive advisor network.

Phare Bio firmographics

Firmographics
Name
Phare Bio
Legal name
Phare Bio Inc.
Website
https://pharebio.org
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Phare Bio industry classification

Industry
Product category
AI-enabled antibiotic drug discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAJAF
Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)

Keywords

  • AI drug discovery
  • Antibiotic discovery platform
  • Antimicrobial resistance therapeutics
  • Generative AI drug design
  • Preclinical drug development

Where Phare Bio is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

Phare Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Philanthropic/Grant Funding: Phare Bio operates as a nonprofit social venture funded primarily through grants and donations. The company addresses the 'valley of death' in preclinical development with donor funding from organizations including TED's Audacious Project, ARPA-H ($27 million), and Google.org
  2. Strategic Commercial Partnerships: Once candidates are derisked through preclinical development, Phare partners with large pharma companies for clinical trials, or spins out new companies. The Basilea partnership includes success-based payments for advancing novel antibiotics
  3. Company Spin-outs: Phare Bio develops a novel pipeline of AI-optimized antibiotic candidates and builds sustainable clinical paths through company spin-outs for long-term sustainability

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Phare Bio product offering

Product offering

Core offering

Phare Bio is a nonprofit social venture that uses generative AI and deep learning (the AIBiotics platform, built with the Collins Lab at MIT) to design and develop novel classes of antibiotics against drug-resistant pathogens. The company performs preclinical discovery and development using donor funding and then advances candidates into clinical trials through strategic pharmaceutical partnerships (e.g., Basilea) or company spin-outs. Its immediate customers are pharmaceutical partners and grant/foundation funders, not end patients.

Product overview

Phare Bio is a social venture offering a unified AI-driven antibiotic discovery platform called AIBiotics. The platform integrates generative AI and deep learning capabilities to design novel antibiotics, followed by hit-to-lead optimization (drug metabolism, toxicology, pharmacokinetics, and efficacy assays) and preclinical development (drug delivery and in vivo efficacy profiling). The company addresses the antibiotic development pipeline from initial discovery through preclinical stages, then partners with large pharma companies or spins out new companies for clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

  • AIBiotics: The world's first generative AI antibiotics discovery engine designed to design and develop novel antibiotics against urgent threats like Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae.

Products and services

  • AIBiotics Generative AI Discovery Platform AIBiotics is Phare Bio's proprietary generative AI and deep learning platform for designing and developing novel antibiotics against drug-resistant pathogens such as Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. It screens 1000x as many molecules, 5x faster, and at 100x greater success rate than conventional approaches, integrating fragment-based screening with de novo compound generation and feeding downstream hit-to-lead optimization and preclinical development. It is used internally by Phare Bio's science team and, via strategic partnerships and spin-outs, is the technology backbone for advancing candidates into clinical development with pharmaceutical partners.

Quantifiable outcome

  • Screens 1000x as many molecules, 5x faster, at 100x greater success rate
  • +2 more outcomes

Companies that use Phare Bio

Customer profile

Segments2 records

Ideal customer profiles2 records

Phare Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Phare Bio partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Basilea PharmaceuticalscoreStrategic or Co-development Partner · 14 April 2026Phare Bio and Basilea Pharmaceuticals partnered to develop antimicrobials, leveraging AI to advance molecules from discovery through clinical trials. The collaboration involves CEO Akhila Kosaraju, MD discussing innovation in antibiotic development.
  • Basilea PharmaceuticacoreStrategic or Co-development Partner · 11 December 2025Basilea Pharmaceutica and Phare Bio entered a partnership to develop a novel antibiotic using AI-driven molecule design. The collaboration aims to address antimicrobial resistance by combining Basilea's anti-infectives industry expertise with Phare's unique AI capabilities. Phare Bio is eligible for success-based payments.
  • Prokaryotics Inc.minorStrategic or Co-development PartnerBasilea announced preclinical partnership with Prokaryotics Inc. for broad-spectrum antifungal development, alongside the Phare Bio partnership for AI-assisted antibiotic discovery.
  • MIT Collins LabcoreStrategic or Co-development PartnerCore partnership with James J. Collins' laboratory at MIT for building the first-ever generative AI platform for novel antibiotic discovery. The lab pioneered AI-driven antibiotic discovery including the halicin breakthrough in 2020 and more recently generative AI-designed antibiotics published in Cell 2025.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Phare Bio competitors and assessment

Company assessment

Direct peers

  • Recursion Pharmaceuticals: AI-enabled drug discovery platform combining high-throughput biology with machine learning to identify novel therapeutics; a direct competitor to Phare in the AI-for-drug-discovery space with publicly disclosed pipeline assets.
  • Insitro: Machine learning-driven drug discovery company using AI/ML platforms to design novel therapeutics — directly comparable to Phare's generative AI approach for antibiotic discovery, though broader in therapeutic scope.
  • Iambic Therapeutics: AI-driven drug discovery company using physics-informed machine learning to design novel small-molecule therapeutics; directly comparable in deploying generative AI for small-molecule design with platform-licensing economics.
  • Schrödinger: Computational chemistry and physics-based drug design platform widely used by pharma; highly comparable as a software-driven small-molecule discovery peer, with both internal pipeline and platform-licensing economics.
  • Absci: AI-powered generative biology platform combining wet-lab and computational methods to design novel antibody therapeutics; comparable platform-based AI drug discovery approach with public-company scale.
  • Kinvard Bio: Harvard spin-out developing a novel class of antibacterials; directly comparable as an early-stage anti-infectives discovery company targeting drug-resistant pathogens, with overlapping scientific founders in the AMR space.
  • Atomwise: AI-driven small molecule drug discovery company using deep learning to design novel therapeutics; comparable platform approach to Phare with broader therapeutic-area focus.
  • ArrePath: AI-enabled antibacterial discovery biotech developing novel antibiotics against drug-resistant pathogens; closely comparable focus area to Phare Bio's anti-infectives mission.
  • Generate Biomedicines: Generative AI platform for designing novel protein-based therapeutics; comparable in deploying generative biology at scale to create drug candidates de novo, though focused on biologics rather than small molecules.

Broad incumbents

  • Isomorphic Labs: Alphabet/DeepMind's drug discovery spin-out using AlphaFold-derived AI for computational drug design; a well-capitalized incumbent applying similar AI methodology to therapeutic discovery at much larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Phare Bio social profiles

Digital presence

Phare Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Phare Bio leadership team

Management profile

Number of profiles

Profiles6 records

Phare Bio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Phare Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phare Bio

What does Phare Bio do?

Phare Bio is a nonprofit social venture that uses generative AI and deep learning (the AIBiotics platform, built with the Collins Lab at MIT) to design and develop novel classes of antibiotics against drug-resistant pathogens. The company performs preclinical discovery and development using donor funding and then advances candidates into clinical trials through strategic pharmaceutical partnerships (e.g., Basilea) or company spin-outs. Its immediate customers are pharmaceutical partners and grant/foundation funders, not end patients.

Is Phare Bio a public or private company?

Phare Bio is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Phare Bio founded?

Phare Bio was founded in 2020. It employs 11 to 50 people.

Where is Phare Bio based?

Phare Bio is headquartered in Boston, United States, in the North America region.

How does Phare Bio make money?

Three revenue lines are on record. Philanthropic/Grant Funding is the primary driver. The others are strategic Commercial Partnerships and company Spin-outs.

Who are Phare Bio's main competitors?

Direct peers on record are Recursion Pharmaceuticals, Insitro, Iambic Therapeutics, Schrödinger, Absci, Kinvard Bio, Atomwise, ArrePath and Generate Biomedicines. Isomorphic Labs is listed as a broad incumbent.

Does Phare Bio have an API?

No public API is recorded for Phare Bio.

What industry is Phare Bio in?

Phare Bio's product category is AI-enabled antibiotic drug discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Mirage NewsAI Speeds Drug Discovery and Design: 3 Key QuestionsJames J. Collins, a professor at MIT and founder of synthetic biology, has been using artificial intelligence and deep learning to discover and design new antibiotics, including the breakthrough antibiotic halicin discovered in 2020 and more recently generating and testing candidate molecules that showed selective antibacterial activity against drug-resistant pathogens. His lab published research in Cell in 2025 demonstrating how generative AI can design antibiotics from scratch, synthesizing 24 compounds of which seven showed antibacterial activity, with two lead candidates (NG1 and DN1) proving effective against drug-resistant bacteria while remaining non-toxic. Collins co-founded Phare Bio, a nonprofit organization, to advance promising antibiotic candidates toward the clinic, and the group recently received a grant from ARPA-H to design 15 new antibiotics as pre-clinical candidates.GlobeNewswireBasilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibioticBasilea Pharmaceutica Ltd of Switzerland announced a partnership with Phare Bio Inc. of Boston, USA, to jointly develop a novel antibiotic using AI-driven drug discovery. Under the agreement, Phare Bio will deploy its Generative AI platform to design molecules with antibacterial properties meeting a predefined target product profile, after which Basilea will assume responsibility for subsequent development in exchange for success-based payments. The partnership represents a new model for antibiotic innovation that combines Phare Bio's AI capabilities with Basilea's drug development expertise to address the urgent global need for novel antibiotics.Business Wire BlogPhare Bio and Basilea Announce Landmark Partnership to Develop Next-Generation Broad-Spectrum Antibiotic Using AIPhare Bio and Basilea Pharmaceutica announced a strategic partnership to develop a novel broad-spectrum antibiotic using AI, aimed at addressing unmet medical needs for patients with serious infections caused by gram-negative pathogens. This collaboration introduces an innovative approach by integrating AI in antibiotic research and development, marking a significant advancement in the field. The partnership is seen as a transformative model for developing essential antibiotics amidst the growing crisis of antimicrobial resistance.The TelegraphFightback: scientists score series of wins in battle against superbugsScientists are achieving breakthroughs in antibiotic discovery, particularly through the use of artificial intelligence by researchers at MIT and Phare Bio to identify new compounds against drug-resistant bacteria. Major pharmaceutical companies like Eli Lilly and GSK are also launching collaborations with tech firms and initiatives to accelerate the development of treatments for superbugs. These efforts aim to reverse a stagnation in drug pipelines and address the growing global threat of antimicrobial resistance.Business Wire BlogPhare Bio Selected to Participate in the Google.org Accelerator: Generative AI to Advance Open-Access Antibiotic Discovery PlatformPhare Bio was selected for the Google.org Accelerator, receiving $30 million in funding and six months of pro bono technical expertise. The company will expand its AI-powered, open-access antibiotic discovery platform, aiming to develop 15 preclinical antibiotics by 2030.Pulse 2.0Phare Bio: Up To $27 Million Award Received From ARPA-HPhare Bio, with MIT and Harvard Wyss Institute, received up to $27 million from ARPA-H to enhance its generative AI antibiotic discovery platform. The funding will generate training data, add filters, and advance 15 preclinical candidates to address antibiotic resistance.YahooPhare Bio receives ARPA-H funds for AI drug discovery platformPhare Bio, with MIT and Harvard, received $27m from ARPA-H to advance its AI drug discovery platform and develop new antibiotics. The grant will generate training data points and support 15 preclinical candidates, aiming to create an open-source database for AI-based antibiotic discovery.Business Wire BlogPhare Bio Awarded Up To $27 Million from ARPA-H to Accelerate AI-Powered Drug Discovery and Develop Critically Needed New Classes of AntibioticsPhare Bio, MIT, and Harvard's Wyss Institute received up to $27 million from ARPA-H to scale its generative AI drug discovery platform. The funds will create an open-source database and advance 15 novel antibiotic candidates. The collaboration aims to address antimicrobial resistance, which is expected to cause 10 million deaths annually by 2050.Business Wire BlogPhare Bio Awarded Up To $27 Million from ARPA-H to Accelerate AI-Powered Drug Discovery and Develop Critically Needed New Classes of AntibioticsPhare Bio, MIT, and Harvard's Wyss Institute received up to $27 million from ARPA-H to scale its generative AI platform for antibiotic discovery. The funds will create an open-source database and advance 15 novel preclinical antibiotic candidates. The collaboration aims to address antimicrobial resistance, which killed nearly 1.3 million people in 2019.Business Wire BlogPhare Bio Awarded Up To $27 Million from ARPA-H to Accelerate AI-Powered Drug Discovery and Develop Critically Needed New Classes of AntibioticsPhare Bio, MIT, and Harvard's Wyss Institute received up to $27 million from ARPA-H to scale its generative AI platform for antibiotic discovery. The funds will create an open-source database and advance 15 novel preclinical antibiotic candidates. The collaboration aims to address antimicrobial resistance, which is expected to cause 10 million deaths annually by 2050.